Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study

被引：2
作者：
Autore, Francesco [1 ]
Visentin, Andrea [2 ]
Deodato, Marina [3 ]
Vitale, Candida [4 ,5 ]
Galli, Eugenio [1 ]
Fresa, Alberto [1 ]
Fazzi, Rita [6 ]
Sanna, Alessandro [7 ]
Olivieri, Jacopo [8 ]
Scortechini, Ilaria [9 ]
Del Principe, Maria Ilaria [10 ]
Sportoletti, Paolo [11 ]
Schiattone, Luana [12 ]
Maschio, Nilla [13 ]
Facchinelli, Davide [14 ]
Marchesi, Francesco [15 ]
Coscia, Marta [4 ,5 ]
Tedeschi, Alessandra [3 ]
Trentin, Livio [2 ]
Innocenti, Idanna [1 ]
Candoni, Anna [8 ,16 ]
Busca, Alessandro [4 ,5 ]
Pagano, Livio [1 ]
Laurenti, Luca [1 ]
机构：
[1] Fdn Policlin Univ A Gemelli IRCCS, Largo Agostino Gemelli 8, I-00168 Rome, Italy
[2] Univ Padua, Padua, Italy
[3] ASST Grande Osped Metropolitano Niguarda, Milan, Italy
[4] Univ Torino, AOU Citta Salute & Sci Torino, Turin, Italy
[5] Univ Torino, Dipartimento Biotecnol Mol & Sci Salute, Turin, Italy
[6] Azienda Osped Univ Pisana, Pisa, Italy
[7] Azienda Osped Univ Careggi, Florence, Italy
[8] Clin Ematol Udine, Udine, Italy
[9] Azienda Osped Univ Marche, Ancona, Italy
[10] Univ Roma Tor Vergata, Dipartimento Biomed & Prevenz, Rome, Italy
[11] AO Santa Maria Misericordia Perugia, Perugia, Italy
[12] Presidio Osped S Spirito Pescara, Pescara, Italy
[13] Oncoematol Ist Oncol Veneto IOV IRCCS, Padua, Italy
[14] Osped San Bortolo, Vicenza, Italy
[15] IRCCS Regina Elena Natl Canc Inst, Rome, Italy
[16] Univ Modena & Reggio Emilia, Modena, Italy
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 05期
关键词：
RITUXIMAB;
D O I：
10.1002/ajh.27247
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：982 / 984
页数：3
相关论文
共 39 条
  • [31] Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
    Herling, Carmen D.
    Cymbalista, Florence
    Gross-Ophoff-Mueller, Carolin
    Bahlo, Jasmin
    Robrecht, Sandra
    Langerbeins, Petra
    Fink, Anna-Maria
    Al-Sawaf, Othman
    Busch, Raymonde
    Porcher, Raphael
    Cazin, Bruno
    Dreyfus, Brigitte
    Ibach, Stefan
    Lepretre, Stephane
    Fischer, Kirsten
    Kaiser, Florian
    Eichhorst, Barbara
    Wentner, Clemens-Martin
    Hoechstetter, Manuela A.
    Doehner, Hartmut
    Leblond, Veronique
    Kneba, Michael
    Letestu, Remi
    Boettcher, Sebastian
    Stilgenbauer, Stephan
    Hallek, Michael
    Levy, Vincent
    LEUKEMIA, 2020, 34 (08) : 2038 - 2050
  • [32] Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab
    Zent, Clive S.
    Wu, Wenting
    Bowen, Deborah A.
    Hanson, Curtis A.
    Pettinger, Adam M.
    Shanafelt, Tait D.
    Kay, Neil E.
    Leis, Jose F.
    Call, Timothy G.
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 476 - 482
  • [33] Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations
    Soumerai, Jacob D.
    Ni, Ai
    Darif, Mohamed
    Londhe, Anil
    Xing, Guan
    Mun, Yong
    Kay, Neil E.
    Shanafelt, Tait D.
    Rabe, Kari G.
    Byrd, John C.
    Chanan-Khan, Asher A.
    Furman, Richard R.
    Hillmen, Peter
    Jones, Jeffrey
    Seymour, John F.
    Sharman, Jeffrey P.
    Ferrante, Lucille
    Mobasher, Mehrdad
    Stark, Thomas
    Reddy, Vijay
    Dreiling, Lyndah K.
    Bhargava, Pankaj
    Howes, Angela
    James, Danelle F.
    Zelenetz, Andrew D.
    LANCET HAEMATOLOGY, 2019, 6 (07): : E366 - E374
  • [34] Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial
    Tournilhac, Olivier
    Le Garff-Tavernier, Magali
    Quoc, Stephanie Nguyen
    Forcade, Edouard
    Chevallier, Patrice
    Legrand-Izadifar, Faezeh
    Damaj, Gandhi Laurent
    Michonneau, David
    Tomowiak, Cecile
    Borel, Cecile
    Orvain, Corentin
    Turlure, Pascal
    Redjou, Rabah
    Guillerm, Gaelle
    Vincent, Laure
    Simand, Celestine
    Lemal, Richard
    Quiney, Claire
    Combes, Patricia
    Pereira, Bruno
    Calvet, Laure
    Cabrespine, Aurelie
    Bay, Jacques-Olivier
    Leblond, Veronique
    Dhedin, Nathalie
    HAEMATOLOGICA, 2021, 106 (07) : 1867 - 1875
  • [35] Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity
    Cheah, Chan Y.
    Nastoupil, Loretta J.
    McLaughlin, Peter
    Fanale, Michelle A.
    Neelapu, Sattva S.
    Fayad, Luis E.
    Hagemeister, Frederick B.
    Fowler, Nathan H.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (03) : 531 - 533
  • [36] Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab
    Zent, Clive S.
    Secreto, Charla R.
    LaPlant, Betsy R.
    Bone, Nancy D.
    Call, Timothy G.
    Shanafelt, Tait D.
    Jelinek, Diane F.
    Tschumper, Renee C.
    Kay, Neil E.
    LEUKEMIA RESEARCH, 2008, 32 (12) : 1849 - 1856
  • [37] Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101
    Jones, Jeffrey A.
    Ruppert, Amy S.
    Zhao, Weiqiang
    Lin, Thomas S.
    Rai, Kanti
    Peterson, Bercedis
    Larson, Richard A.
    Marcucci, Guido
    Heerema, Nyla A.
    Byrd, John C.
    LEUKEMIA & LYMPHOMA, 2013, 54 (12) : 2654 - 2659
  • [38] Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
    Burger, Jan A.
    Robak, Tadeusz
    Demirkan, Fatih
    Bairey, Osnat
    Moreno, Carol
    Simpson, David
    Munir, Talha
    Stevens, Don A.
    Dai, Sandra
    Cheung, Leo W. K.
    Kwei, Kevin
    Lal, Indu
    Hsu, Emily
    Kipps, Thomas J.
    Tedeschi, Alessandra
    LEUKEMIA & LYMPHOMA, 2022, 63 (06) : 1375 - 1386
  • [39] Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)-beta- glucopyranose beta- glucan is well tolerated and achieves high complete remission rates
    Zent, Clive S.
    Call, Timothy G.
    Bowen, Deborah A.
    Conte, Michael J.
    LaPlant, Betsy R.
    Witzig, Thomas E.
    Ansell, Stephen M.
    Weiner, George J.
    LEUKEMIA & LYMPHOMA, 2015, 56 (08) : 2373 - 2378
1234